
Sign up to save your podcasts
Or


Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.
By STAT4.5
320320 ratings
Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.

1,967 Listeners

766 Listeners

1,093 Listeners

821 Listeners

496 Listeners

124 Listeners

6,089 Listeners

60 Listeners

85 Listeners

34 Listeners

5,530 Listeners

56 Listeners

23 Listeners

403 Listeners

15 Listeners

13 Listeners